(Q42510237)

1 November 2017

Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan (English)

1 reference

1 November 2017

1 reference

1 reference

1

1 reference

1 November 2017

2

1 reference

1 November 2017

10

1 reference

1 November 2017

6

Giordano Dicuonzo

1 reference

1 November 2017

7

Laura Rocci

1 reference

1 November 2017

5

Fabrizio Battistoni

1 reference

1 November 2017

4

Michele Gavasci

1 reference

1 November 2017

9

Nicola Gebbia

1 reference

1 November 2017

Antonio Russo

3

1 reference

PubMed ID

17391070

1 November 2017

Valerio Maria Rosaria

series ordinal

8

1 reference

1 November 2017

1 April 2007

1 reference

1 November 2017

1 reference

1 November 2017

8

1 reference

1 November 2017

4

1 reference

1 November 2017

319-327

1 reference

New chemotherapy approaches in colorectal cancer

1 November 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Critical evaluation of current treatments in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Why the epidermal growth factor receptor? The rationale for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

The epidermal growth factor receptor and its inhibition in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

The EGF receptor family as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Epidermal growth factor receptor dependence in human tumors: more than just expression?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Raf-1 protein kinase is an integral component of the oncogenic signal cascade shared by epidermal growth factor and platelet-derived growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Systems analysis of circadian time-dependent neuronal epidermal growth factor receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Molecular determinants of cetuximab efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.4.319

21 January 2018

Identifiers

DOI

10.2217/14622416.8.4.319

1 reference

1 November 2017

1 reference

PubMed ID

17391070